Besides improving lipid accumulation in the liver, LXRβ-selective and LXRα/β-dual antagonism may lead to hypercholesterolemia in nonhuman primates [198], which represents a barrier to the development of LXR antagonist as a therapy for NAFLD. This evidence concerns the gene NR1H2 and Hypercholesterolemia.